Fierce Pharma

With FDA approval, Roche's blood cancer bispecific Lunsumio goes subcutaneous

Three years after its initial FDA approval, Roche has made up for an early disadvantage with its blood cancer drug Lunsumio ...

FDA approves Roche’s Lunsumio VELO™ for subcutaneous use in relapsed or refractory follicular lymphoma

Lunsumio VELO reduces administration time from 2-4 hours to approximately one minuteAvailability of Lunsumio VELO allows treatment aligned to people’s clinical needs and personal preferences Approval ...
pharmaphorum

J&J's subcutaneous Rybrevant cleared by FDA

The green light for Rybrevant Faspro – which combines amivantamab with hyaluronidase – means that the drug is the first ...

FDA Approves Genentech’s Lunsumio VELO™ for Subcutaneous Use in Relapsed or Refractory Follicular Lymphoma

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved CD20xCD3 bispecific Lunsumio VELO™ ...
CURE

FDA Green Lights 'One-Minute' Injection for R/R Follicular Lymphoma Treatment

The FDA granted accelerated approval to Lunsumio VELO for adults with relapsed/refractory follicular lymphoma after two or ...
Medical Dialogues

Roche Lunsumio VELO bags USFDA approval for subcutaneous use in follicular lymphoma

Basel: Roche has received approval from the US Food and Drug Administration (FDA) for CD20xCD3 bispecific Lunsumio VELO ...
Fierce Pharma

J&J scores FDA nod for subcutaneous lung cancer shot, sharpening its challenge to Tagrisso

J&J has hypothesized that subcutaneous absorption of the drug may potentially enhance immune-mediated anticancer activity.
CURE

Rybrevant Faspro FDA-Approved as First Sub-Q Therapy for EGFR NSCLC

The U.S. Food and Drug Administration (FDA) have granted approval to Rybrevant Faspro (amivantamab and hyaluronidase-lpuj), ...
PharmExec

FDA Approves Lunsumio VELO for Adults with Relapsed or Refractory Follicular Lymphoma

Roche’s FDA approval of Lunsumio VELO as a one-minute subcutaneous bispecific therapy for relapsed or refractory follicular ...
Medical Dialogues

JnJ wins USFDA approval for subcutaneous Rybrevant Faspro for EGFR-Mutated NSCLC

Horsham: Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has approved RYBREVANT FASPRO ...
Pharmaceutical Technology on MSN

MEDIPOST, Teikoku Seiyaku partner for CARTISTEM commercialisation in Japan

MEDIPOST has announced a multi-year exclusive partnership with Teikoku Seiyaku to commercialise CARTISTEM, an allogeneic stem ...

Fortis surgeon explains how obesity and visceral fat increases surgical risks; shares 4 ways bariatric surgery can help

Dr Sharma explains how high concentrations of visceral fat interferes during surgical procedures. He suggests bariatric surgery as an effective way to curb it.